

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**CSPC PHARMACEUTICAL GROUP LIMITED**

石藥集團有限公司

*(Incorporated in Hong Kong under the Companies Ordinance)*

*(Stock Code: 1093)*

**VOLUNTARY ANNOUNCEMENT  
PRODUCT LICENSING AGREEMENT**

The board of directors (the **Board**) of CSPC Pharmaceutical Group Limited (the **Company**) is pleased to announce that on 9 December 2016, CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd\* (石藥集團中奇製藥技術(石家莊)有限公司) (**CSPC Zhongqi**), a wholly owned subsidiary of the Company, entered into an agreement (the **Agreement**) with Casper Pharma Limited (**Casper**), in relation to the product licensing and commercialization of a complex generic oncology drug (the **Product**) in the United States of America (the **United States**). The Product was developed by CSPC Zhongqi and already marketed in China.

Pursuant to the Agreement, CSPC Zhongqi agrees to grant an exclusive right to Casper to perform the necessary clinical studies and apply for the relevant approvals required for the manufacture, distribution and sale of the Product in the United States and to exclusively distribute and sell the Product in the United States.

Upon successful launch of the Product in the United States, CSPC Zhongqi shall supply the Product exclusively to Casper, and Casper shall purchase exclusively from CSPC Zhongqi such quantities of the Product that Casper requires for distribution and sale in the United States. CSPC Zhongqi will be entitled to receive a prescribed percentage of the net sales of the Product in the United States by Casper as sales royalty. In addition, Casper will make sales milestone payments to CSPC Zhongqi of up to an aggregate amount of US\$101,000,000 subject to the amount of sales of the Product in the United States.

Casper is a pharmaceutical company engaged in the acquisition, sales and marketing of brand pharmaceutical products for the prescription drug market in the United States.

*\* For identification purpose only*

By order of the Board  
**CSPC Pharmaceutical Group Limited**  
**CAI Dong Chen**  
*Chairman*

Hong Kong, 12 December 2016

*As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. CHAK Kin Man, Mr. PAN Weidong, Mr. WANG Shunlong, Mr. WANG Huaiyu, Mr. LU Jianmin, Mr. WANG Zhenguo, Mr. WANG Jinxu and Mr. LU Hua as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director; and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Mr. LO Yuk Lam, Mr. YU Jinming and Mr. CHEN Chuan as independent non-executive directors.*

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表示概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。



**CSPC PHARMACEUTICAL GROUP LIMITED**

**石藥集團有限公司**

(根據公司條例於香港註冊成立)

(股份代號：1093)

自願公告  
產品授權協議

石藥集團有限公司（「本公司」）董事會（「董事會」）欣然宣佈，於二零一六年十二月九日，本公司之全資附屬公司石藥集團中奇製藥技術（石家莊）有限公司（「石藥中奇」）與 Casper Pharma Limited（「Casper」）訂立協議（「該協議」），內容有關一種高端抗腫瘤仿製藥（「該產品」）在美利堅合眾國（「美國」）之產品授權及商業化。該產品由石藥中奇開發，並已在中國市場銷售。

根據該協議，石藥中奇同意向 Casper 授出獨家權利，以令 Casper 可進行所需臨床試驗，並申請於美國製造、分銷及銷售該產品之相關批准，及於美國獨家分銷及銷售該產品。

成功於美國推出該產品後，石藥中奇將獨家向 Casper 供應該產品，而 Casper 將獨家向石藥中奇購買 Casper 於美國分銷及銷售所需之該產品數量。石藥中奇將享有權利按淨銷售收入的某個百分比向 Casper 收取該產品在美國之銷售提成。此外，Casper 將向石藥中奇作出最高總額為 101,000,000 美元之銷量里程碑付款（取決於該產品於美國之銷售額）。

Casper 為一家以美國處方藥為目標市場，從事品牌醫藥產品之收購、銷售及市場推廣之醫藥公司。

代表董事會  
石藥集團有限公司  
蔡東晨  
主席

香港，二零一六年十二月十二日

於本公告日期，本公司董事會成員包括執行董事蔡東晨先生、翟健文先生、潘衛東先生、王順龍先生、王懷玉先生、盧建民先生、王振國先生、王金戌先生及盧華先生；非執行董事李嘉士先生；以及獨立非執行董事陳兆強先生、王波先生、盧毓琳先生、于金明先生及陳川先生。